Genetic alterations in the complement system have been linked to a variety of diseases, including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and age-related macular degeneration (AMD). We performed sequence analysis of the complement genes complement factor H (CFH), complement factor I (CFI), and complement C3 (C3) in 866 aHUS/ C3G and 697 AMD patients. In total, we identified 505 low-frequency alleles, representing 121 unique variants, of which 51 are novel. CFH contained the largest number of unique lowfrequency variants (n = 64; 53%), followed by C3 (n = 32; 26%) and CFI (n = 25; 21%). A substantial number of variants were found in both patients groups (n = 48; 40%), while 41 (34%) variants were found only in aHUS/C3G and 32 (26%) variants were AMD specific. Genotypephenotype correlations between the disease groups identified a higher frequency of protein altering alleles in short consensus repeat 20 (SCR20) of factor H (FH), and in the serine protease domain of factor I (FI) in aHUS/C3G patients. In AMD, a higher frequency of protein-altering alleles was observed in SCR3, SCR5, and SCR7 of FH, the SRCR domain of FI, and in the MG3 domain of C3. In conclusion, we observed a substantial overlap of variants between aHUS/C3G and AMD; however, there is a distinct clustering of variants within specific domains.
| INTRODUCTION
The complement system is part of the innate immune system, which balances host protection and immune defense. The complement system can be activated via 3 pathways: the classical, lectin, and alternative pathways, which converge at the step of cleavage of the central component C3 into C3a and C3b. C3b bound to activated factor B (Bb) forms the alternative pathway C3 convertase (C3bBb), which cleaves and activates more C3 molecules, thereby amplifying the cascade. When the alternative pathway C3 convertase binds additional C3b molecules, the C5 convertase is formed (C3bBbC3b), which cleaves C5 into C5a and C5b. C5b interacts with C6, C7, C8, and multiple C9 molecules to form the membrane attack complex (C5b-9). Regulators, such as factor H (FH) and membrane cofactor protein (MCP; CD46), can inhibit complement activation by accelerating the decay of the C3 convertases or by acting as a cofactor for factor I (FI). 1 Deregulation of the complement system, specifically the alternative pathway, has been implicated in a variety of diseases. 1 Remarkably, protein-altering variants in genes of the complement system have been associated with very different clinical outcomes: atypical Maartje J. Geerlings and Elena B. Volokhina contributed equally to this study.
hemolytic uremic syndrome (aHUS; MIM# 235400), C3 glomerulopathy (C3G; or dense deposit disease), and age-related macular degeneration (AMD; MIM# 603075). 2, 3 aHUS is a rare disorder characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. It is estimated that genetic variants in the complement factor H (CFH), complement factor I (CFI), complement C3 (C3), complement factor B (CFB), CD46 molecule (CD46), thrombomodulin, and diacylglycerol kinase epsilon genes, the presence of genomic rearrangement in the CFH/CFH-related (CFHR) gene cluster, and autoantibodies to FH account for 60% of all aHUS cases. [4] [5] [6] C3G is another rare renal illness, which is characterized by C3 deposition in the glomeruli of the kidney and can lead to renal failure.
C3G pathogenesis is linked to the presence of autoantibodies that stabilize the alternative and classical pathway C3 convertases (C3Nef and C4Nef ). Genetic aberrations in the CFH, CFI, C3, CD46, CFHR5 genes, genomic rearrangements in the CFH/CFHR gene cluster, and anti-FH autoantibodies genes have been described in 20% of C3G patients. [6] [7] [8] AMD, in contrast to aHUS and C3G, is a common disease in which gradual visual impairment occurs at older age due to degeneration of the central retina. 
| Genetic screening
In this study, we focused on the complement genes associated with both aHUS/C3G and AMD, which includes the CFH (HGNC:4883, MIM# 134370), CFI (HGNC:5394, MIM# 217030), and C3
(HGNC:1318, MIM# 120700) genes. 4, 5, 9, 22 Genetic analysis was performed for the aHUS/C3G and AMD cohorts using DNA isolated from peripheral blood leucocytes using standard procedures. For the AMD cohort, whole-exome sequencing Only low-frequency and rare variants (minor allele frequency < 5%)
based on the ExAC database 25 were taken into account. Thus, common variants previously described as associated with the disease (such as Tyr402His and Ile62Val in AMD and polymorphisms described by Caprioli et al in aHUS) 26, 27 have not been taken into account. Variants were considered aHUS/C3G or AMD specific when found only in the aHUS/C3G or AMD cohorts analyzed in this study and in previously published reports. Reported odds ratios for genetic variants in AMD were recently published by the International AMD Genomics Consortium. 9, 10 Annotation of the variants, including minor allele frequency of the ExAC database, were obtained using ANNOVAR. 28 
| Statistical analysis
Statistical analyses were performed using SPSS Software for Windows version 22.0 (Fisher exact, 2-sided, weighted by number). We calculated if there was a higher percentage of alleles within a specific protein domain of FH, FI, or C3 in aHUS/C3G compared to AMD, and vice versa. P values <.05 were considered as significant.
| Protein structure analysis
Protein domains that carried a significantly higher percentage of alleles in aHUS/C3G or AMD were analyzed in more depth. The potential effect of the variants mapping to these domains on interactions between C3b, FH and FI and their possible effect on C3b regulation were studied. To this end, the variants were mapped on the available molecular structures of the C3b-miniFH-FI protein complex (protein data bank, PDB 5O32
29
). Protein structures were retrieved from the PDB (www.rcsb.org) 30 using YASARA. 31 
| Literature search
We performed a literature search to review low-frequency coding non-synonymous and canonical splice-site variants in CFH, CFI, and Table S1 in Appendix S1).
The 505 alleles represent 121 unique low-frequency variants, of which 51 are novel and 70 were previously reported in literature (Table S2 in Appendix S1). Of the 51 novel variants identified, 8 variants in CFH (n = 4), CFI (n = 2), and C3 (n = 2) lead to a premature stop, frameshift or abolished splice site, thereby leading to the loss of protein function. The remaining 43 novel variants lead to missense alterations or to an in-frame insertion (Table S3 in Appendix S1).
CFH contained the largest number of unique low-frequency variants (n = 64). Two-third of these variants were aHUS/C3G (24/64) or AMD-specific (17/64), and one-third was found in both patients groups (23/64) ( Figure 1 ; Table S3 in Appendix S1). Three of the lowfrequency variants (p.Gln950His, p.Asn1050Tyr, p.Gln1143Glu) identified in CFH in aHUS/C3G patients, were previously reported to have a protective effect for AMD. 10 The p.Gln950His variant was detected in 15 aHUS/C3G patients, the p.Asn1050Tyr variant was detected in 21 aHUS/C3G patients, and the p.Gln1143Glu variant was detected in 9 aHUS/C3G patients.
In CFI, 25 unique low-frequency variants were identified of which 15 were found in both patient groups. Only 4 of the 25 variants were specific for aHUS/C3G and 6 variants were exclusively found in AMD ( Figure 1 ; Table S3 in Appendix S1).
In C3, 32 unique low-frequency variants were identified. These variants were distributed between aHUS/C3G-specific variants (13/32), AMD-specific variants (9/32), and both phenotypes (10/32) ( Figure 1 ; Table S3 in Appendix S1). ) compared to aHUS/C3G (Table 1) .
For FH, we calculated the cumulative effect for the alleles found in the domains involved in cofactor activity, which include N-terminal SCR1-4 and C-terminal SCR19-20. We observed a burden of alleles in the SCR19-20 domains at the C-terminus for aHUS/C3G (21.3% vs 3.6% in AMD, P = 1.44 × 10 A previous study illustrates an interaction of FH SCR7 with glycosaminoglycan (GAG) analogues; however, none of the residues that were altered in our cohorts were implicated in contact with GAGs (Table S3 in Appendix S1). Genetic variants identified in 886 aHUS/C3G patients and 697 AMD patients. Colors represent the phenotype in which the variants were identified: green (both in aHUS/C3G and AMD), orange (aHUS/C3G only), blue (AMD only) or green^(with circumflex) (protective for AMD but found recurrently in aHUS/C3G). Protein domains that carried a significantly higher percentage of alleles in aHUS/C3G or AMD are colored gray. Protein interaction sites are reported underneath the domains with dotted lines. Only low frequency variants (minor allele frequency <5%) based on the ExAC database are shown. CFA, cofactor activity; DAA, decay-accelerating activity; CRP, C-reactive protein respectively ( Figure 3C ). The residues Pro553 and Glu548, affected by genetic variants identified in aHUS/C3G and AMD, are located in one of the activation loops in proximity to the FI active site ( Figure 3D ).
The AMD-associated variants, affecting the SRCR domain of FI, are not located at the interface with C3b or FH (Figure 2 ).
| aHUS/C3G and AMD variants found in literature
To compare the results of our study with previously reported variants,
we compiled a list of low-frequency variants found in literature for aHUS, C3G, and AMD (Table S4 in Appendix S1). We identified an additional 441 unique variants resulting in an amino acid change or splice site in CFH (n = 236), CFI (n = 104), and C3 (n = 101). These variants were found in aHUS/C3G (n = 212), AMD (n = 189), and both phenotypes (n = 40) (Table S5 in Appendix S1).
| DISCUSSION
In aHUS/C3G patients, we observed a higher frequency of proteinaltering alleles in the C-terminal SCR20 domain of FH and in the SP Percentage of variant alleles identified with significant P-values in bold.
domain of FI (Figure 1 ). In AMD patients, an increased frequency of protein-altering alleles was observed in the N-terminal SCR domains of FH, specifically domains SCR3, SCR5, and SCR7, in addition to the SRCR domain of FI, and the MG3 domain of C3.
| Complement FH
The SCR20 domain of FH, which is thought to interact with both C3b, C-reactive protein, and endothelial cells, harbors significantly more aHUS-/C3G-associated genetic variants. Amino acids affected by genetic variants in this domain do not interact directly with C3b
( Figure 2 ), but are probably to mediate FH attachment to the cell surface. Reduced binding to C3b and C3d was previously observed for variants p.Val1197Ala and p.Arg1210Cys in CFH (Table S3 in Appendix S1), which may be explained by the role of these residues in the overall structure of the FH C-terminal domains.
Interestingly, like SCR20, SCR19 of FH is also described to be important for interaction with the thioester-containing domain (TED)
domain of C3b and C3d, and for cell-surface interactions. However, for SCR 19, we observed only 11 protein altering alleles for aHUS/ C3G and none for AMD. Only variant CFH p.Gln1143Glu, protective for AMD, 9,10 was detected (Table S3 in Appendix S1), indicating the importance of genetic changes in this domain for the pathogenesis of renal disease. Since phenotype-specific prevalence of genetic variants in the TED domain of C3 for renal disease was not discovered by us or described in literature (Tables S3 and S4 (Table S4 in Appendix S1). Previous studies in densely affected AMD families detected several AMD-specific variants in the first 4 SCR domains of FH (eg, p.Asp90Glu, p.Arg175Pro, p.Arg175Gln, p.Cys192Phe, and p.Ser193Leu), underscoring the importance of these domains in the disease pathogenesis of AMD. 12, 22, 33 Previously, more than 60% of the aHUS-associated FH mutations were reported in the Cterminal domains. 21 Variants in this region interfere with heparin, C3b, and C3d binding, and result in reduced cell-surface interaction. 34, 35 The low-frequency variants reported in AMD are located at the N-terminal domains of FH and decrease cofactor activity for the FI-mediated cleavage of C3b.
12,22 The C-terminal domains of FH are a hot spot for genetic variants in renal diseases, but not AMD, and are essential in endothelial binding of FH. 36 Interestingly, the retinal Bruch's membrane differs from the renal glomerular basement membrane in GAG-binding sites. 37 It is hypothesized that not FH but Factor H-like 1 (FHL-1), the short form of FH (SCR1-7), is involved in the pathogenesis of AMD. FHL-1 has the same regulatory functions as FH, but due to its size only this FH form can diffuse into Bruch's membrane and drusen in the eye. 38, 39 This may explain why the genetic alterations at the C-terminaldomains of FH, which are not present in FHL-1, are less prevalent in AMD than in renal disease. Consistently, the SCR19-20 region of FH localizes to GAGs in the glomeruli. 37 Importance of specific GAG binding in AMD is further underscored by the effect of the common polymorphism Tyr402His located in SCR7 on binding of heparan sulfates. 32 Moreover, our data show a higher allelic frequency in SCR7.
The residues found altered in our cohorts do not make direct contact with GAGs; however, genetic variants may still influence interactions by introducing conformational changes to make patients more prone to AMD.
Overall, C3b interactions with glomerular endothelium in the kidney may be more important than the interaction with the endothelium in the retina for maintaining the tissue homeostasis. Furthermore, our data underscore the importance of N-terminal region of FH in C3b regulation in AMD.
Three variants in CFH (c.2850G > T, p.Gln950His; c.3148A > T, p.
Asn1050Tyr; c.3427C > G, p.Gln1143Glu) were reported as protective for AMD 10 . CFH p.Gln950His, residing in SCR16, is associated with disease risk for aHUS with moderate effect on cofactor function. 40 CFH p.Asn1050Tyr, in SCR18, is a polymorphism reported various times in aHUS without functional analyses. [41] [42] [43] No information is available on CFH p.Gln1143Glu and its association with aHUS/C3G.
The protective mechanisms of these variants in AMD remain to be elucidated.
| Complement factor I
In this study, we observed that genetic changes in the SP domain of FI are more prevalent in aHUS/C3G than in AMD patients. The SP domain, together with the FI membrane attack complex (FIMAC) domain, contains binding sites that are important for C3b and C4b degradation. 44, 45 Variants found in the SP domain could interfere with proper cofactor activity. Residues Arg406 and Lys441 in the SP domain make contacts with Glu123 and Asn136 of FH, respectively ( Figure 3C ). Interestingly, a CFI variant affecting Arg448, found in AMD, is located in close proximity to these residues, within the charged loop (435-448) that is important in interaction with various C3b regulators ( Figure 3C ). 29 The CFI residues Pro553 and Glu548 are located in one of the activation loops in proximity to the FI active site ( Figure 3D ), 46 while Ile340 at the N-terminus of the light chain plays a role in stabilizing of the oxyanion hole. 29 The residue Tyr459 is a part of the hydrophobic patch, which is important in heavy chain/light chain contact of FI. 29 Furthermore, we observed a clustering of alleles in the SRCR domain in AMD patients (Tables S3 and S4 in Appendix S1 
| Complement component 3
In this study, an increased number of variants were found in the MG3 domain of C3 in AMD patients (Tables S3 and S4 in Appendix S1).
There are no interactions known for the MG3 domain in C3b, including that with FB or complement inhibitors. 48, 49 However, MG3 is located at the predicted interface between C3b and C3 in the C3bBb-C3 enzyme-substrate complex. Genetic alterations in MG3 may thus result in changes at this interface and in more efficient C3 activation by C3 convertase. 50 Therefore, AMD variants affecting the residues in the MG3 domain may affect the overall domain structure and the rates of C3 secretion and/or activation into C3b.
In literature, the majority of variants were identified in the TED domain for both aHUS/C3G (22/40) and AMD (14/53) ( Table S4 in Appendix S1). For aHUS, it was previously reported that the TED, MG2, and MG5 domains of C3 exhibited most of the missense mutations. 16 Variant identified in aHUS/C3G were found in the TED (8.9%) and MG2 (50%) domains. For AMD, we did not identify any variants in the TED domain, but the majority of variants identified resided in MG2 (52.5%) as well.
| Clinical relevance
Detailed analysis of rare genetic variants that are phenotype specific or that are not, and the variability in which certain domains have significant associations with renal or AMD phenotypes will generate valuable insights into disease mechanisms. A deeper understanding of domain-specific effects in these diseases will allow for the development of novel therapeutic interventions. Targeting protein domains, rather than the entire protein, increases specificity and reduces any potential side effects. A combination of genetic and functional analyses will probably become instrumental in diagnostics as well as stratifying patients for highly specific personalized treatment.
In conclusion, our data underscore the importance of the Nterminal domains of FH in AMD, and of the FH C-terminal domains in renal disease. In AMD, alterations in the SRCR domain of FI are prevalent, while FI changes related to renal disease are predominantly found in structural elements around the active site. For C3, AMD alterations were located in the MG3 domain. We observed a substantial overlap in variants between aHUS/C3G and AMD; however, there is a distinct clustering of variants within specific domains.
Depending on the location of the variant, the genetic variants follow a distinctive genotype-phenotype correlation. Some genetic variants are associated with aHUS, C3G, and AMD but individuals carrying these risk variants only present phenotypic characteristics of one disorder. 17, 51 It is probably not always one specific variant that results in the manifestation of aHUS, C3G, or AMD, but a combination of rare and common disease specific risk variants and environmental factors will lead to the manifestation of either an eye or renal phenotype.
